Summary of Purpose
Atrial fibrillation (AF) is the most common cardiac arrhythmia with a lifetime risk of developing AF of 1 in 4 people aged over 40. Stroke remains the most feared complication of AF with an increase in risk by 5-fold, and is the leading cause of morbidity and mortality. The left atrial appendage (LAA) is the origin for more than 90% of the emboli in non-valvular AF. The WATCHMAN™ Left Atrial Closure Device...Read More →
The following dates are available for this trial. Trial information last updated on 13 September 2016.
|1 Oct 2015||20 May 2015||1 Oct 2016||1 Feb 2017||1 Sep 2016||Unavailable|
|Start Date||First Received||1st Completion||Completion||Verification||Results|
- Masking: Open Label
- Intervention: Single Group Assignment
- Mindy Vroomen, Dr.
- Mindy Vroomen, MD